Company
Relay Therapeutics
2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
fulvestrant 2capivasertib 1RLY-2608 1palbociclib 1ribociclib 1
Trials
2 of 3 trials shown
-
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Zovegalisibcapivasertib FDA EUfulvestrant FDA EU
One or more known primary oncogenic PIK3CA mutation(s)
PIK3CA activating mutationPIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
-
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RLY-2608fulvestrant FDA EUpalbociclib FDA EUribociclibPF-07220060 100mgPF-07220060 300 mg
One or more documented primary oncogenic PIK3CA mutation(s) in blood and/or tumor per local assessment
PIK3CA activating mutationPIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
-
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
RLY-5836fulvestrant FDA EUpalbociclib FDA EUribociclibabemaciclib
One or more documented primary oncogenic PIK3CA mutation(s) in blood and/or tumor per local assessment
PIK3CA activating mutationPIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
No trials match these filters.